Axplora, a global CDMO for API small molecule and ADC manufacturing, announces the investment of €50 million in its Mourenx site in Southwest France. Specializing in large-scale API industrial chemistry and chromatography, this project will enhance Mourenx’s capabilities, positioning it as a center of excellence in the Axplora network for contract manufacturing of APIs and drug substances for FDA-approved biologics.

Upgrading infrastructure and capabilities at Mourenx enhances its peptide purification in a biologics environment to support the development of next-gen therapies, including GLP-1 drugs that target diabetes and obesity.

“GLP-1 therapies represent a paradigm shift in medicine, offering targeted therapies for complex diseases with unprecedented efficacy and tolerability,” said Arul Ramadurai, Chief Commercial Officer. “This initiative, built on strong customer partnerships, reinforces Axplora’s role as a trusted partner in manufacturing life-changing, breakthrough medicines.”

“This project is testament to our pioneering expertise in industrial chromatography, and working closely with our client, we target having the facility BLA-ready in 15 months. To achieve this our internal teams are working closely with partners in a strong cross-functional project team, well-supported by the local authorities. We are looking forward to a bright future at Mourenx,” stated Dr. Pere Patón-Morales, Chief Operating Officer.

Construction and infrastructure development will begin immediately, with first supplies of GLP-1 therapies expected in 2026.